Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.
Academic Article
Overview
abstract
This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.
